Showing results (971-980 of 2,413) with videos related to
Sort By:
Pageof 242
Journal of Medical Economics|October 1, 2020
Economic burden of subsequent fracture in osteoporosis patients in South KoreaJae-A Park, Jin Hyun Nam, Sung-Hyun Hong, et al.Journal of Medical Economics|December 4, 2020
Effect of direct oral feeding following minimally invasive esophagectomy on costs and quality of lifeMadhuri Pattamatta, Laura F C Fransen, Annemarie C P Dolmans-Zwartjes, et al.Journal of Medical Economics|December 10, 2020
Identifying disability level in multiple sclerosis patients in a U.S.-based health plan claims databaseRegina Berkovich, Edward Fox, Annette Okai, et al.Journal of Medical Economics|January 19, 2021
The cost-effectiveness of glasdegib in combination with low-dose cytarabine, for the treatment of newly diagnosed acute myeloid leukemia in adult patients who are not eligible to receive intensive induction chemotherapy in CanadaYannan Hu, Majed Charaan, Ilse van Oostrum, et al.Journal of Medical Economics|January 19, 2021
Hospitalizations and healthcare costs associated with rifaximin versus lactulose treatment among commercially insured patients with hepatic encephalopathy in the United StatesMichael L Volk, Rebecca Burne, Annie Guérin, et al.Journal of Medical Economics|January 19, 2021
Excess healthcare costs in patients with autosomal dominant polycystic kidney disease by renal dysfunction stagePatrick Gagnon-Sanschagrin, Yawen Liang, Myrlene Sanon, et al.Journal of Medical Economics|January 20, 2021
Humanistic burden among caregivers of patients with Alzheimer's disease or dementia in Japan: a large-scale cross-sectional surveyShinya Ohno, Yirong Chen, Hiroyuki Sakamaki, et al.Journal of Medical Economics|November 12, 2021
Budget impact analysis of the DiviTum TKa assay in postmenopausal women with hormone receptor positive metastatic breast cancerJosh J Carlson, Gregory F Guzauskas, Robert A Dann, et al.Journal of Medical Economics|December 20, 2021
Cost-effectiveness of brentuximab vedotin for relapsed or refractory systemic anaplastic large-cell lymphoma in ChinaJia Liu, Lei Zheng, Ling-Hsiang ChuangJournal of Medical Economics|January 6, 2022
The societal economic value of COVID-19 vaccines in the United StatesNoam Kirson, Elyse Swallow, Jessica Lu, et al.Pageof 242